Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis

A significant proportion of patients with osteogenic sarcoma die from lung metastasis within 5 years of diagnosis. Molecular signatures that predict pulmonary metastasis from primary osteogenic sarcoma and identify those patients at risk would be clinically useful as prognostic markers. Protein expression profiles of two clonally related murine osteogenic sarcoma cell lines with low (K12) and high (K7M2) metastatic potential were compared using two different proteomic technologies, two‐dimensional difference gel electrophoresis and cell profiling by matrix‐assisted laser desorption/ionization mass spectrometry. Interrogation of a molecular pathways network database suggested several additional candidate molecules that potentially predict metastatic potential of primary osteogenic sarcoma. Two such proteins, macrophage migration inhibitory factor and tumour necrosis factor were selected for further validation studies. Western blots confirmed increased expression of both cytokines in K7M2 cells compared to K12 cells. Levels of migration inhibitory factor and tumour necrosis factor were semi‐quantitatively measured in human osteogenic sarcoma samples by immunohistochemistry and were correlated with clinicopathologic parameters and patient outcomes. Multivariate survival analysis demonstrated that tumour necrosis factor expression in chemotherapy naïve osteogenic sarcoma is an independent prognostic factor for overall and metastasis‐free survival. No significant differences in adverse outcomes were observed based on macrophage migration inhibitory factor expression.

[1]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[2]  T. Lóránd,et al.  Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. , 2009, Current medicinal chemistry.

[3]  Christian Pilarsky,et al.  Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. , 2009, The Journal of surgical research.

[4]  A. Huvos,et al.  Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[5]  The UniProt Consortium,et al.  The Universal Protein Resource (UniProt) 2009 , 2008, Nucleic Acids Res..

[6]  C. Sturgeon,et al.  A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  K. Moon,et al.  Expression of Macrophage Migration Inhibitory Factor Relates to Survival in High-grade Osteosarcoma , 2008, Clinical orthopaedics and related research.

[8]  G. Semenza,et al.  Macrophage Migration Inhibitory Factor Activates Hypoxia-Inducible Factor in a p53-Dependent Manner , 2008, PloS one.

[9]  B. Aggarwal,et al.  TNF: a master switch for inflammation to cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[10]  P. Choong,et al.  A review of clinical and molecular prognostic factors in osteosarcoma , 2008, Journal of Cancer Research and Clinical Oncology.

[11]  Valentin A. Pavlov,et al.  Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. , 2007, Journal of medicinal chemistry.

[12]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[13]  R. Caprioli,et al.  Multivariable Difference Gel Electrophoresis and Mass Spectrometry , 2007, Molecular & Cellular Proteomics.

[14]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[15]  S. Stošić-Grujičić,et al.  Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. , 2006, International immunopharmacology.

[16]  Y. Xie,et al.  Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma , 2006, Oncogene.

[17]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[18]  Yu Shyr,et al.  Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  John A Thompson,et al.  Immunochemical and proteomic analysis of covalent adducts formed by quinone methide tumor promoters in mouse lung epithelial cell lines. , 2005, Chemical research in toxicology.

[20]  J. Healey,et al.  Cell Proliferation of Cultured Human Cancer Cells are Affected by the Elevated Tumor Pressures that Exist In Vivo , 2005, Annals of Biomedical Engineering.

[21]  T. Ganesan,et al.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Morand.  New therapeutic target in inflammatory disease: macrophage migration inhibitory factor , 2005, Internal medicine journal.

[23]  Lisa L. Wang.  Biology of osteogenic sarcoma. , 2005, Cancer journal.

[24]  Richard M Caprioli,et al.  Tissue Profiling by Mass Spectrometry , 2005, Molecular & Cellular Proteomics.

[25]  Fumiaki Sasaki,et al.  Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Richard M Caprioli,et al.  Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics , 2004, Cancer Research.

[27]  M. DeWitte,et al.  Tumor necrosis factor-α in the pathogenesis and treatment of cancer , 2004 .

[28]  M. Gebhardt,et al.  Biology and therapeutic advances for pediatric osteosarcoma. , 2004, The oncologist.

[29]  R. Caprioli,et al.  Proteome analysis of human colon cancer by two‐dimensional difference gel electrophoresis and mass spectrometry , 2004, Proteomics.

[30]  Stephen M Hewitt,et al.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.

[31]  Tyson V. Sharp,et al.  Gene expression array profile of human osteosarcoma , 2003, British Journal of Cancer.

[32]  P. Meltzer,et al.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Mu Wang,et al.  Proteomic analysis of differential protein expression induced by ultraviolet light radiation in HeLa cells , 2003, Proteomics.

[34]  P. Szlosarek,et al.  Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .

[35]  S. Todo,et al.  An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. , 2000, Cytokine.

[36]  Yuji Sato,et al.  Macrophage Migration Inhibitory Factor (MIF) , 1996 .

[37]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[38]  V. Erfle,et al.  Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. , 1988, Differentiation; research in biological diversity.

[39]  W. Fiers,et al.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity , 1988, The Journal of experimental medicine.

[40]  D. Brantley-Sieders,et al.  Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. , 2009, Cancer research.

[41]  S. Mocellin,et al.  TNF and cancer: the two sides of the coin. , 2008, Frontiers in bioscience : a journal and virtual library.

[42]  P. Szlosarek,et al.  Tumour necrosis factor-alpha as a tumour promoter. , 2006, European journal of cancer.

[43]  B. Hoang,et al.  Osteosarcoma: basic science and clinical implications. , 2006, The Orthopedic clinics of North America.

[44]  L. Helman,et al.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential , 2004, Clinical & Experimental Metastasis.

[45]  R. Mitchell.  Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. , 2004, Cellular signalling.

[46]  J. Yokota,et al.  Biological properties and gene expression associated with metastatic potential of human osteosarcoma , 2004, Clinical & Experimental Metastasis.

[47]  P. Szlosarek,et al.  Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. , 2003, The Lancet. Oncology.

[48]  Yuji Sato,et al.  Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. , 2003, Annals of the New York Academy of Sciences.